SAN FRANCISCO—Finasteride and dutasteride are similarly effective for treating lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia in properly selected patients, but dutasteride is associated with significantly greater sexual side effects and breast complications, researchers reported.
SAN FRANCISCO—Prostate cancer is associated with significantly increased urinary bother in community-dwelling older men with lower urinary tract symptoms (LUTS), data suggest.
Decreased peak flow rate and a history of hypertension and/or diabetes are significantly associated with CKD in men with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH), according to investigators in Seoul, Korea.
Almost 68% of diabetic Taiwanese men younger than 45 years reported having erectile dysfunction.
A study of 602 Korean men with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia found that those with a waist circumference greater than 90 cm (central obesity) had a 36% increased risk of severe LUTS compared with men who had smaller waists.
Amlodipine plus terazosin achieved better BP control that either drug alone, according to researchers.
Rapid increases in irritative lower urinary tract symptoms (LUTS) and rapid decreases in peak urinary flow rates may be related to inflammatory processes, new research suggests.
Patients who receive alfuzosin as treatment for benign prostatic hyperplasia (BPH) experience improvements in sexual function as well lower urinary tract symptoms (LUTS), a South Korean study suggests.
Physical activity reduces the risk of BPH and lower urinary tract symptoms (LUTS), according to a review of studies that included a total of 43,083 men.
